Title | Diabetes and Alzheimer's Disease: Can Elevated Free Copper Predict the Risk of the Disease? |
Publication Type | Journal Article |
Year of Publication | 2017 |
Authors | Squitti, R, Mendez, AJ, Simonelli, I, Ricordi, C |
Journal | J Alzheimers Dis |
Volume | 56 |
Issue | 3 |
Pagination | 1055-1064 |
Date Published | 2017 |
ISSN | 1875-8908 |
Abstract | BACKGROUND: Defective copper regulation, primarily referred to as chelatable redox active Cu(II), has been involved in the etiology of diabetes, and Alzheimer's disease (AD). OBJECTIVES: However, no study has determined levels of labile copper non-bound to ceruloplasmin (non-Cp Cu, also known as 'free' copper) in the blood of subjects with diabetes compared with that of AD patients. METHODS: To this aim, values of non-Cp Cu were measured in 25 Type 1 (T1D) and 31 Type 2 (T2D) subjects and in28 healthy controls, along with measurements of C-reactive protein, glycated hemoglobin A1c, cholesterol, and triglycerides. Non-Cp Cu levels were compared with those of an AD group previously studied. RESULTS: T2D subjects had significantly higher non-Cp Cu levels than Controls and T1D subjects (both p CONCLUSION: These results suggest the involvement of catalytically-active Cu(II) and glucose dysregulation in oxidative stress reactions leading to tissue damage in both diseases. |
DOI | 10.3233/JAD-161033 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 27983558 |
PubMed Central ID | PMC5302029 |